18F-fluorodeoxyglucose uptake and tumor hypoxia: Revisit 18F-fluorodeoxyglucose in oncology application

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 240-247

  Li, Xiao Feng ^a,b   Du, Yang ^c   Ma, Yuanyuan ^b   Postel, Gregory C ^a   Civelek, A Cahid ^a  

^a University of Louisville School of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUTE OF AUTOMATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CARBONATE DEHYDRATASE IX; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HOE 33342; PIMONIDAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; ASCITES TUMOR; AUTORADIOGRAPHY; BREAST CANCER; CARCINOMATOUS PERITONITIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG UPTAKE; EHRLICH ASCITES TUMOR; HUMAN; HUMAN CELL; HYPOXIA; LUNG NON SMALL CELL CANCER; MOUSE; NEOPLASM; NONHUMAN; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR XENOGRAFT;

EID: 84902437397     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.010     Document Type: Article

References (32)

1. Warburg O (1956). On the origin of cancer cells. Science 123, 309-314.
2. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
3. Clavo AC, Brown RS, and Wahl RL (1995). Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36, 1625-1632.
4. Burgman P, O'Donoghue JA, Humm JL, and Ling CC (2001). Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 42, 170-175.
5. 18F]FDG in cultured prostate cancer cells. Nucl Med Biol 33, 977-984.
6. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, and Overgaard J (2008). Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 35, 2294-2303.
7. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, and Humm JL (2005). Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62, 545-553.
8. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, and Overgaard J (2008). Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122, 2726-2734.
9. 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med 53, 1262-1268.
10. Cheran SK, Nielsen ND, and Patz Jr EF (2004). False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR Am J Roentgenol 182, 1129-1132.
11. Iwano S, Ito S, Tsuchiya K, Kato K, and Naganawa S (2013). What causes falsenegative PET findings for solid-type lung cancer? Lung Cancer 79, 132-136.
12. 18F-FDG. J Nucl Med 49, 22-29.
13. 18F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings. Am J Nucl Med Mol Imaging 3, 142-153.
14. Li XF, Carlin S, Urano M, Russell J, Ling CC, and O'Donoghue JA (2007). Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 67, 7646-7653.
15. Li XF and O'Donoghue JA (2008). Hypoxia in microscopic tumors. Cancer Lett 264, 172-180.
16. 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med 51, 632-638.
17. 131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 37, 339-348.
18. Bertout JA, Patel SA, and Simon MC (2008). The impact of O2 availability on human cancer. Nat Rev Cancer 8, 967-975.
19. Macheda ML, Rogers S, and Best JD (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202, 654-662.
20. Yasuda S, Arii S, and Mori A, et al (2004). Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1α and its significance. J Hepatol 40, 117-123.
21. Wyatt E, Wu R, Rabeh W, Park HW, Ghanefar M, and Ardehali H (2010). Regulation and cytoprotective role of hexokinase III. PLoS One 5, e13823.
22. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, and Gores GJ (2005). Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42, 358-364.
23. 18F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of cisplatinresistant ovarian cancer. Transl Oncol 6, 586-595.
24. Kayed H, Meyer P, He Y, Kraenzlin B, Fink C, Gretz N, Schoenberg SO, and Sadick M (2012). Evaluation of the metabolic response to cyclopamine therapy in pancreatic cancer xenografts using a clinical PET-CT system. Transl Oncol 5, 335-343.
25. Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, and Sticker-Jantscheff M, et al (2010). Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Transl Oncol 3, 264-275.
26. Thomlinson RH and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
27. Li XF, Jiang H, Ma Y, Huang T, Yin X, Civelek AC, and Shen B (2013). A model system for PET radiopharmaceuticals validation: focusing on tumor microenvironment. Int J Med Phys Clin Eng Radiat Oncol 2, 19-29. http://dx.doi.org/10.4236/ijmpcero.2013.21004.
28. Vaupel P, Schlenger K, Knoop C, and Höckel M (1991). Oxygenation of human tumors-evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51, 3316-3322.
29. Nordsmark M, Overgaard M, and Overgaard J (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41, 31-39.
30. Li XF, Ma Y, and Jiang H (2012). Understanding hypoxia microenvironment of micro-metastases. J Solid Tumors 2(2), 28-33.
31. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, and Dewhirst MW (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38, 285-289.
32. 18F-fluorothymidine PET achieves more complete identification of viable lung cancer cells in mice and patients than individual radiopharmaceutical: a proof-of-concept study. Transl Oncol 6, 755-783.